U.S., Sept. 23 -- ClinicalTrials.gov registry received information related to the study (NCT07186283) titled 'Pharmacokinetic Study of a Novel Cannabidiol (CBD) Formulation in Healthy Volunteers' on Sept. 05.
Brief Summary: The purpose of this study is to test a new formulation of cannabidiol (CBD) to see how it is processed in the body and how safe it is for healthy volunteers. CBD is a compound found in the cannabis plant that has shown potential to help treat various medical and mental health conditions. While there is already an approved CBD-based drug that is used for epilepsy in the UK, called Epidyolex, most CBD formulations have poor absorption when taken orally, reducing their effectiveness and often requiring higher doses.
NW Ph...